2025 Q3 -tulosraportti
49 päivää sitten36 min
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
445
Myynti
Määrä
1 270
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | ENS | NON | ||
| 55 | ENS | DDB | ||
| 638 | NON | DDB | ||
| 1 000 | NON | NON | ||
| 2 516 | NON | NON |
Ylin
12VWAP
Alin
11,6VaihtoMäärä
0,9 80 625
VWAP
Ylin
12Alin
11,6VaihtoMäärä
0,9 80 625
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 9 052 | 2 800 | +6 252 | 0 |
| Nordea Bank Abp | 4 239 | 0 | +4 239 | 0 |
| SSW Market Making GmbH | 6 389 | 7 414 | −1 025 | 0 |
| Nordnet Bank AB | 47 050 | 49 354 | −2 304 | 39 657 |
| Danske Bank A/S | 3 600 | 6 592 | −2 992 | 446 |
| Avanza Bank AB | 10 295 | 14 465 | −4 170 | 8 717 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 10 295 | 14 465 | −4 170 | 8 717 |
| Danske Bank A/S | 3 600 | 6 592 | −2 992 | 446 |
| Nordnet Bank AB | 47 050 | 49 354 | −2 304 | 39 657 |
| SSW Market Making GmbH | 6 389 | 7 414 | −1 025 | 0 |
| Nordea Bank Abp | 4 239 | 0 | +4 239 | 0 |
| Skandinaviska Enskilda Banken AB | 9 052 | 2 800 | +6 252 | 0 |
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·6 t sittenUpdate from CEO Ulrik 18.01.2026 Back from JPM 2026 — and encouraged by how clearly Curasight's strategy resonated across the meetings. Radionuclide theranostics has decisively moved from promise to execution. At JPM, discussions about Curasight were concrete and focused: uPAR as a biologically validated target, the strength of combining uTRACE-diagnostik® with uTREAT-terapi®, and the value of a true theranostic platform built for clinical translation. There was great interest in where we are right now: -> advancing our clinical programs, -> executing on short-term milestones, -> and preparing for the next value inflection points as data matures. What stood out was the shift in dialogue. Conversations were less about explaining the rationale and more about timelines, differentiation, scalability, and partnership avenues. This reflects both the maturity of the radionuclide field and the growing confidence in focused, biology-driven approaches like ours. With important clinical advancements ahead, 2026 is shaping up to be a pivotal year for Curasight – and for radionuclide therapy more generally. Thanks to everyone who took the time to participate in thoughtful, direct, and forward-looking discussions. JPM may be over, but the work — and the momentum — clearly continues. uTREAT + uTRACE = uROCK 😉 https://www.linkedin.com/posts/ulrich-krasilnikoff-aaa7901_back-from-jpm-2026-and-encouraged-by-how-activity-7418773133265969152-SFYI?utm_medium=ios_app&rcm=ACoAAFZlEboBitt49OByT-lCdkdnCNkmFngKZ4E&utm_source=social_share_send&utm_campaign=copy_link
·4 t sittenIt's really great that they are so quick to release something. Even though it's "just" a social media post, it demonstrates confidence and great belief in what they have spent time on before, during, and after JPM. That's impactful. An exciting year ahead.
·7 t sittenMonday can hardly get any better (see attached picture); CEO Ulrich K. comments on the recently concluded JP Morgan Health conference and something is brewing for....well, read for yourself :) 🙌👏
·1 päivä sitten · MuokattuI have created a strategic narrative/description of Curasight from an investor perspective (for full documentation, please refer to Master and Appendix in previously shared material) Market consensus seems to be: “Phase I, topline in 2026 - there is plenty of time.” In my assessment, that is a major misreading of reality. Curasight expects to have recruited all six patients in Phase I within the coming months, with topline in Q2 2026 – probably early in Q2. The process indicates low clinical and operational friction. At the same time, management states that they are engaged in strategic discussions towards the next value-creating step, which is after Phase I. My clear assessment is that dialogues with major Big Pharma players have already taken place in connection with JPM, under NDA and with sharing of non-public data, both for FPD and probably also 2nd patient. At this stage, Big Pharma does not look at endpoints, but whether the fundamental prerequisites are in place: ✔ Target validation in humans ✔ Retention for dosimetry ✔ No early safety or toxicity warnings ✔ A program without friction ✔ A disciplined and data-driven management 👉The only open question is variance and reproducibility (patient 3–6). Bottom line: The next value-creating step for Curasight is not necessarily topline results. In theranostics, history has repeatedly shown that value creation can just as well come in the form of a strategic partnership agreement, an optioned structure - or simply by a Big Pharma decision already having been made, long before the market becomes aware of it. The market waits for topline --> Big Pharma waits for patterns. Link to the narrative/description: https://drive.google.com/file/d/1MEqltPss2Y5kjbcg7Vyv9Ifv86R0ig9T/view?usp=drive_link ------------------------------------------------------------------------------------ Disclaimer: This is not a buy recommendation. The material has been prepared solely for personal use and reflection. I myself own shares in Curasight.- ·2 päivää sittenOut of pure boredom (and since it's now the weekend and we might as well speculate a little); Curium posted this little teaser video on YouTube two days ago...and doesn't it just implicitly scream 'Curasight' ;)?? https://youtu.be/Dc39iOsT-fw?si=tZHMMcKzWI2dNdEL Curasight's 'motto', "what you see is what you treat" is almost paraphrased 1-1 in the video ("Treat what you see, see what you treat" ). How big is the possibility that Curium and Curasight will expand the partnership agreement...?·16 t sittenUnless everything collapses (and one has to admit that this technology cannot be used in practice, then Curasight will quite simply be a central player in a revolution in this field). Regarding the paraphrasing, you can in a video from September, if I remember correctly, see Andreas yes - almost verbatim - present as she does. It's absolutely wild. But then again, it is an established partnership and it's the same technology they are talking about, so that is precisely the principle. But it is and remains just a seal of approval for how cheap Curasight still is. Because if you have a technology that in 1-2-3 years actually proves useful in TREATMENT that seems to work - then it will feel like a fairy tale to sit as a Dane and have discovered it as an RH Spinoff from the early 00s. Like a cheat code one used (and got rich). Unless one ends up getting screwed over and bought out too cheaply, there's a pretty good chance of getting rich on Curasight within the next few years. Nothing is certain in the world, but if you have 10.000, I would much rather put them into Curasight than lottery tickets for all the money, even if you got x2 lottery tickets for free on top.
- ·3 päivää sittenAnyone expecting an update from Ulrich and co. here post JP Morgan? There are a couple of interesting things currently, _ dare one address the elephant in the room now or should it remain in the room for months without further info (that the company itself has announced that post uTreat prlm, data they had what was needed for Big Pharma to assess the case). _ dare one trust that a status update will come soon - which will clarify the process from here and 6-18 months ahead. That was something that worked incredibly well last year. The case needs the timeline to be clarified before too long, as it previously just stated "uTrace preliminary efficacy data and topline results ph2 (with Curium) in H1 2026. " Silence is probably not entirely bad for once, isolated, as at this stage it might be difficult to communicate certain things before they actually happen. Or what - I'm actually a bit unsure if one is allowed/could consider addressing any interest that has arisen for the case post. JP Morgan. Because that probably borders on market manipulation... Just like one cannot announce when money will come from Curium, even if one might have a presumption... I think? There are extremely many interesting things lurking around the corner, but they have to remain hidden.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
49 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenUpdate from CEO Ulrik 18.01.2026 Back from JPM 2026 — and encouraged by how clearly Curasight's strategy resonated across the meetings. Radionuclide theranostics has decisively moved from promise to execution. At JPM, discussions about Curasight were concrete and focused: uPAR as a biologically validated target, the strength of combining uTRACE-diagnostik® with uTREAT-terapi®, and the value of a true theranostic platform built for clinical translation. There was great interest in where we are right now: -> advancing our clinical programs, -> executing on short-term milestones, -> and preparing for the next value inflection points as data matures. What stood out was the shift in dialogue. Conversations were less about explaining the rationale and more about timelines, differentiation, scalability, and partnership avenues. This reflects both the maturity of the radionuclide field and the growing confidence in focused, biology-driven approaches like ours. With important clinical advancements ahead, 2026 is shaping up to be a pivotal year for Curasight – and for radionuclide therapy more generally. Thanks to everyone who took the time to participate in thoughtful, direct, and forward-looking discussions. JPM may be over, but the work — and the momentum — clearly continues. uTREAT + uTRACE = uROCK 😉 https://www.linkedin.com/posts/ulrich-krasilnikoff-aaa7901_back-from-jpm-2026-and-encouraged-by-how-activity-7418773133265969152-SFYI?utm_medium=ios_app&rcm=ACoAAFZlEboBitt49OByT-lCdkdnCNkmFngKZ4E&utm_source=social_share_send&utm_campaign=copy_link·4 t sittenIt's really great that they are so quick to release something. Even though it's "just" a social media post, it demonstrates confidence and great belief in what they have spent time on before, during, and after JPM. That's impactful. An exciting year ahead.
- ·7 t sittenMonday can hardly get any better (see attached picture); CEO Ulrich K. comments on the recently concluded JP Morgan Health conference and something is brewing for....well, read for yourself :) 🙌👏
- ·1 päivä sitten · MuokattuI have created a strategic narrative/description of Curasight from an investor perspective (for full documentation, please refer to Master and Appendix in previously shared material) Market consensus seems to be: “Phase I, topline in 2026 - there is plenty of time.” In my assessment, that is a major misreading of reality. Curasight expects to have recruited all six patients in Phase I within the coming months, with topline in Q2 2026 – probably early in Q2. The process indicates low clinical and operational friction. At the same time, management states that they are engaged in strategic discussions towards the next value-creating step, which is after Phase I. My clear assessment is that dialogues with major Big Pharma players have already taken place in connection with JPM, under NDA and with sharing of non-public data, both for FPD and probably also 2nd patient. At this stage, Big Pharma does not look at endpoints, but whether the fundamental prerequisites are in place: ✔ Target validation in humans ✔ Retention for dosimetry ✔ No early safety or toxicity warnings ✔ A program without friction ✔ A disciplined and data-driven management 👉The only open question is variance and reproducibility (patient 3–6). Bottom line: The next value-creating step for Curasight is not necessarily topline results. In theranostics, history has repeatedly shown that value creation can just as well come in the form of a strategic partnership agreement, an optioned structure - or simply by a Big Pharma decision already having been made, long before the market becomes aware of it. The market waits for topline --> Big Pharma waits for patterns. Link to the narrative/description: https://drive.google.com/file/d/1MEqltPss2Y5kjbcg7Vyv9Ifv86R0ig9T/view?usp=drive_link ------------------------------------------------------------------------------------ Disclaimer: This is not a buy recommendation. The material has been prepared solely for personal use and reflection. I myself own shares in Curasight.
- ·2 päivää sittenOut of pure boredom (and since it's now the weekend and we might as well speculate a little); Curium posted this little teaser video on YouTube two days ago...and doesn't it just implicitly scream 'Curasight' ;)?? https://youtu.be/Dc39iOsT-fw?si=tZHMMcKzWI2dNdEL Curasight's 'motto', "what you see is what you treat" is almost paraphrased 1-1 in the video ("Treat what you see, see what you treat" ). How big is the possibility that Curium and Curasight will expand the partnership agreement...?·16 t sittenUnless everything collapses (and one has to admit that this technology cannot be used in practice, then Curasight will quite simply be a central player in a revolution in this field). Regarding the paraphrasing, you can in a video from September, if I remember correctly, see Andreas yes - almost verbatim - present as she does. It's absolutely wild. But then again, it is an established partnership and it's the same technology they are talking about, so that is precisely the principle. But it is and remains just a seal of approval for how cheap Curasight still is. Because if you have a technology that in 1-2-3 years actually proves useful in TREATMENT that seems to work - then it will feel like a fairy tale to sit as a Dane and have discovered it as an RH Spinoff from the early 00s. Like a cheat code one used (and got rich). Unless one ends up getting screwed over and bought out too cheaply, there's a pretty good chance of getting rich on Curasight within the next few years. Nothing is certain in the world, but if you have 10.000, I would much rather put them into Curasight than lottery tickets for all the money, even if you got x2 lottery tickets for free on top.
- ·3 päivää sittenAnyone expecting an update from Ulrich and co. here post JP Morgan? There are a couple of interesting things currently, _ dare one address the elephant in the room now or should it remain in the room for months without further info (that the company itself has announced that post uTreat prlm, data they had what was needed for Big Pharma to assess the case). _ dare one trust that a status update will come soon - which will clarify the process from here and 6-18 months ahead. That was something that worked incredibly well last year. The case needs the timeline to be clarified before too long, as it previously just stated "uTrace preliminary efficacy data and topline results ph2 (with Curium) in H1 2026. " Silence is probably not entirely bad for once, isolated, as at this stage it might be difficult to communicate certain things before they actually happen. Or what - I'm actually a bit unsure if one is allowed/could consider addressing any interest that has arisen for the case post. JP Morgan. Because that probably borders on market manipulation... Just like one cannot announce when money will come from Curium, even if one might have a presumption... I think? There are extremely many interesting things lurking around the corner, but they have to remain hidden.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
445
Myynti
Määrä
1 270
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | ENS | NON | ||
| 55 | ENS | DDB | ||
| 638 | NON | DDB | ||
| 1 000 | NON | NON | ||
| 2 516 | NON | NON |
Ylin
12VWAP
Alin
11,6VaihtoMäärä
0,9 80 625
VWAP
Ylin
12Alin
11,6VaihtoMäärä
0,9 80 625
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 9 052 | 2 800 | +6 252 | 0 |
| Nordea Bank Abp | 4 239 | 0 | +4 239 | 0 |
| SSW Market Making GmbH | 6 389 | 7 414 | −1 025 | 0 |
| Nordnet Bank AB | 47 050 | 49 354 | −2 304 | 39 657 |
| Danske Bank A/S | 3 600 | 6 592 | −2 992 | 446 |
| Avanza Bank AB | 10 295 | 14 465 | −4 170 | 8 717 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 10 295 | 14 465 | −4 170 | 8 717 |
| Danske Bank A/S | 3 600 | 6 592 | −2 992 | 446 |
| Nordnet Bank AB | 47 050 | 49 354 | −2 304 | 39 657 |
| SSW Market Making GmbH | 6 389 | 7 414 | −1 025 | 0 |
| Nordea Bank Abp | 4 239 | 0 | +4 239 | 0 |
| Skandinaviska Enskilda Banken AB | 9 052 | 2 800 | +6 252 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
2025 Q3 -tulosraportti
49 päivää sitten36 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr, FactSet| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 27.2. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 1.12.2025 | |
| 2025 Q2 -tulosraportti | 28.8.2025 | |
| 2025 Q1 -tulosraportti | 25.4.2025 | |
| 2024 Q4 -tulosraportti | 27.2.2025 | |
| 2024 Q3 -tulosraportti | 21.11.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·6 t sittenUpdate from CEO Ulrik 18.01.2026 Back from JPM 2026 — and encouraged by how clearly Curasight's strategy resonated across the meetings. Radionuclide theranostics has decisively moved from promise to execution. At JPM, discussions about Curasight were concrete and focused: uPAR as a biologically validated target, the strength of combining uTRACE-diagnostik® with uTREAT-terapi®, and the value of a true theranostic platform built for clinical translation. There was great interest in where we are right now: -> advancing our clinical programs, -> executing on short-term milestones, -> and preparing for the next value inflection points as data matures. What stood out was the shift in dialogue. Conversations were less about explaining the rationale and more about timelines, differentiation, scalability, and partnership avenues. This reflects both the maturity of the radionuclide field and the growing confidence in focused, biology-driven approaches like ours. With important clinical advancements ahead, 2026 is shaping up to be a pivotal year for Curasight – and for radionuclide therapy more generally. Thanks to everyone who took the time to participate in thoughtful, direct, and forward-looking discussions. JPM may be over, but the work — and the momentum — clearly continues. uTREAT + uTRACE = uROCK 😉 https://www.linkedin.com/posts/ulrich-krasilnikoff-aaa7901_back-from-jpm-2026-and-encouraged-by-how-activity-7418773133265969152-SFYI?utm_medium=ios_app&rcm=ACoAAFZlEboBitt49OByT-lCdkdnCNkmFngKZ4E&utm_source=social_share_send&utm_campaign=copy_link·4 t sittenIt's really great that they are so quick to release something. Even though it's "just" a social media post, it demonstrates confidence and great belief in what they have spent time on before, during, and after JPM. That's impactful. An exciting year ahead.
- ·7 t sittenMonday can hardly get any better (see attached picture); CEO Ulrich K. comments on the recently concluded JP Morgan Health conference and something is brewing for....well, read for yourself :) 🙌👏
- ·1 päivä sitten · MuokattuI have created a strategic narrative/description of Curasight from an investor perspective (for full documentation, please refer to Master and Appendix in previously shared material) Market consensus seems to be: “Phase I, topline in 2026 - there is plenty of time.” In my assessment, that is a major misreading of reality. Curasight expects to have recruited all six patients in Phase I within the coming months, with topline in Q2 2026 – probably early in Q2. The process indicates low clinical and operational friction. At the same time, management states that they are engaged in strategic discussions towards the next value-creating step, which is after Phase I. My clear assessment is that dialogues with major Big Pharma players have already taken place in connection with JPM, under NDA and with sharing of non-public data, both for FPD and probably also 2nd patient. At this stage, Big Pharma does not look at endpoints, but whether the fundamental prerequisites are in place: ✔ Target validation in humans ✔ Retention for dosimetry ✔ No early safety or toxicity warnings ✔ A program without friction ✔ A disciplined and data-driven management 👉The only open question is variance and reproducibility (patient 3–6). Bottom line: The next value-creating step for Curasight is not necessarily topline results. In theranostics, history has repeatedly shown that value creation can just as well come in the form of a strategic partnership agreement, an optioned structure - or simply by a Big Pharma decision already having been made, long before the market becomes aware of it. The market waits for topline --> Big Pharma waits for patterns. Link to the narrative/description: https://drive.google.com/file/d/1MEqltPss2Y5kjbcg7Vyv9Ifv86R0ig9T/view?usp=drive_link ------------------------------------------------------------------------------------ Disclaimer: This is not a buy recommendation. The material has been prepared solely for personal use and reflection. I myself own shares in Curasight.
- ·2 päivää sittenOut of pure boredom (and since it's now the weekend and we might as well speculate a little); Curium posted this little teaser video on YouTube two days ago...and doesn't it just implicitly scream 'Curasight' ;)?? https://youtu.be/Dc39iOsT-fw?si=tZHMMcKzWI2dNdEL Curasight's 'motto', "what you see is what you treat" is almost paraphrased 1-1 in the video ("Treat what you see, see what you treat" ). How big is the possibility that Curium and Curasight will expand the partnership agreement...?·16 t sittenUnless everything collapses (and one has to admit that this technology cannot be used in practice, then Curasight will quite simply be a central player in a revolution in this field). Regarding the paraphrasing, you can in a video from September, if I remember correctly, see Andreas yes - almost verbatim - present as she does. It's absolutely wild. But then again, it is an established partnership and it's the same technology they are talking about, so that is precisely the principle. But it is and remains just a seal of approval for how cheap Curasight still is. Because if you have a technology that in 1-2-3 years actually proves useful in TREATMENT that seems to work - then it will feel like a fairy tale to sit as a Dane and have discovered it as an RH Spinoff from the early 00s. Like a cheat code one used (and got rich). Unless one ends up getting screwed over and bought out too cheaply, there's a pretty good chance of getting rich on Curasight within the next few years. Nothing is certain in the world, but if you have 10.000, I would much rather put them into Curasight than lottery tickets for all the money, even if you got x2 lottery tickets for free on top.
- ·3 päivää sittenAnyone expecting an update from Ulrich and co. here post JP Morgan? There are a couple of interesting things currently, _ dare one address the elephant in the room now or should it remain in the room for months without further info (that the company itself has announced that post uTreat prlm, data they had what was needed for Big Pharma to assess the case). _ dare one trust that a status update will come soon - which will clarify the process from here and 6-18 months ahead. That was something that worked incredibly well last year. The case needs the timeline to be clarified before too long, as it previously just stated "uTrace preliminary efficacy data and topline results ph2 (with Curium) in H1 2026. " Silence is probably not entirely bad for once, isolated, as at this stage it might be difficult to communicate certain things before they actually happen. Or what - I'm actually a bit unsure if one is allowed/could consider addressing any interest that has arisen for the case post. JP Morgan. Because that probably borders on market manipulation... Just like one cannot announce when money will come from Curium, even if one might have a presumption... I think? There are extremely many interesting things lurking around the corner, but they have to remain hidden.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Spotlight Stock Market DK
Määrä
Osto
445
Myynti
Määrä
1 270
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 500 | ENS | NON | ||
| 55 | ENS | DDB | ||
| 638 | NON | DDB | ||
| 1 000 | NON | NON | ||
| 2 516 | NON | NON |
Ylin
12VWAP
Alin
11,6VaihtoMäärä
0,9 80 625
VWAP
Ylin
12Alin
11,6VaihtoMäärä
0,9 80 625
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Skandinaviska Enskilda Banken AB | 9 052 | 2 800 | +6 252 | 0 |
| Nordea Bank Abp | 4 239 | 0 | +4 239 | 0 |
| SSW Market Making GmbH | 6 389 | 7 414 | −1 025 | 0 |
| Nordnet Bank AB | 47 050 | 49 354 | −2 304 | 39 657 |
| Danske Bank A/S | 3 600 | 6 592 | −2 992 | 446 |
| Avanza Bank AB | 10 295 | 14 465 | −4 170 | 8 717 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Avanza Bank AB | 10 295 | 14 465 | −4 170 | 8 717 |
| Danske Bank A/S | 3 600 | 6 592 | −2 992 | 446 |
| Nordnet Bank AB | 47 050 | 49 354 | −2 304 | 39 657 |
| SSW Market Making GmbH | 6 389 | 7 414 | −1 025 | 0 |
| Nordea Bank Abp | 4 239 | 0 | +4 239 | 0 |
| Skandinaviska Enskilda Banken AB | 9 052 | 2 800 | +6 252 | 0 |